ACADIA Pharmaceuticals is an integrated drug discovery company engaged in the validation of therapeutic targets and the identification of novel lead compounds for pharmaceutical development. ACADIA has developed a platform of proprietary breakthrough technologies for rapid analysis of gene function.  ACADIA’s technology, including the patented Receptor Selection and Amplification Technology (R-SAT™), allows the Company to exploit the paradigm shift occurring in the pharmaceutical industry, whereby novel drug targets are increasingly identified through genomic initiatives.

Agouron Pharmaceuticals, Inc. was organized in 1984 to bring a fresh approach to the discovery of new therapeutic drugs for treatment of cancer, AIDS and other serious diseases. Agouron has developed and mobilized an engineering approach to the design of novel synthetic drugs based upon the molecular structures of target proteins which play key roles in human disease. Known as protein structure-based drug design, this approach uses innovations from a variety of scientific disciplines and substantially overcomes the technical barriers to traditional drug discovery. From this technology, Agouron has built a new kind of foundation for one of the pharmaceutical industry's most elusive assets: a real product pipeline.

Air Products is a worldwide supplier of industrial gases and equipment, specialty and intermediate chemicals, and environmental and energy systems.

The world's largest independent biotechnology company, Amgen, was founded in Thousand Oaks, California in 1980 as AMGen (Applied Molecular Genetics). Amgen's corporate mission is to be the world leader in developing and delivering important, cost-effective therapeutics based on advanced cellular and molecular biology.

ARIAD is a leader in the design and development of a new class of pharmaceuticals that target intracellular signaling pathways to alter the course of disease. The Company is concentrating the majority of its resources on four drug discovery programs. The first three programs involve developing small molecules that inhibit signaling pathways in cells responsible for allergy/asthma, immune-related disorders and osteoporosis. The fourth program employs small molecules to gain control of signaling pathways, providing a means to regulate the production of therapeutic proteins by engineered cells within the body.

ArQule, Inc. is a leading chemistry company in accelerated drug discovery using its high throughput lead generation and lead optimization technologies. ArQule provides new pathways to product discovery by integrating five core technologies - - modular building blocks technology, structure - guided design, high speed parallel chemical synthesis, information technology and an Automated Molecular Assembly Plant (AMAPTM) parallel synthesis system to accelerate the identification and optimization of drug and product development candidates in the pharmaceutical, biotechnology, and agrochemical industries. ArQule is based in Medford, Massachusetts.

Analytical Services of Delaware Inc. presents New and Innovative Chromatography Applications & Analytical Services for Industries.
Searching out new and diverse libraries of Organic and Natural Compounds
Setting New Standards in Control and Preparation of Organic Compounds
Special Attention and dedication to High Throughput Screening Programs

Astra is an international pharmaceutical company in a phase of rapid growth. The company focuses on areas of disease in which its proficiency in research can satisfy important medical needs.

AXYS Pharmaceuticals, Inc.  is a leader in the integration of drug discovery technologies - from gene identification through clinical development, and is focused on the discovery of small molecule therapeutics. The company has research collaborations with world class pharmaceutical companies, covering a broad range of therapeutic areas including respiratory, cardiovascular, metabolic, and infectious disease, as well as oncology and central nervous system disorders.

Barr Laboratories, Inc. is a leading independent developer, manufacturer and marketer of high quality off-patent pharmaceuticals. Founded in 1970, the company ranks among the top ten independent companies in the approximately $7 billion U.S. generic pharmaceutical business. With 1996 net sales of nearly $232 million, the company manufactures and distributes a wide range of prescription drug products including antibiotics, cardiovascular agents, and cancer treatments.

Bayer Diagnostics is a health care company that develops, manufactures and markets clinical chemistry, immunodiagnostics, diabetes, hematology and urinalysis systems for central laboratory, point-of-care and self testing customer segments.

Biogen, Inc., headquartered in Cambridge, MA, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering.  Biogen’s research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy.

Boehringer Ingelheim is one of the leading pharmaceutical companies in the world with more than 140 subsidiaries and over 22.000 employees, the Boehringer Ingelheim Corporation is represented on every continent, the key areas include Europe, Japan and North America. With a total sales turnover of more than 6 billion Deutsch Marks, Boehringer ranks twentieth among the major pharmaceutical concerns worldwide.

Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders and cancer. The company is also a leader in consumer medicines, orthopaedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin care products.

Chiron Corporation is a global healthcare company headquartered in Emeryville, California, near San Francisco. As one of the world's largest biotechnology companies, Chiron employs more than 6,500 people in facilities on four continents. The company is uniquely positioned to combine therapeutic, blood testing, vaccine and research strategies in many disease areas, including cardiovascular and infectious diseases and cancer.

The research strengths of Biomolecular Engineering are the quality of our people and the range of their expertise. Our research skills in molecular biology, cell biology and protein chemistry assist us in the search for new pharmaceuticals, diagnostics and medical devices. The division is the lead member of the Pharmaceutical and Human Health Sector. CSIRO Biomolecular Engineering seeks collaborative arrangements with commercial and other significant research and development groups. The scientific and commercial outcomes of our research are carefully managed to maximise the benefits to our industry partners and to protect the scientific knowledge for the benefit of Australia.

Cubist Pharmaceuticals, Inc. is focused on the discovery, development and commercialization of novel antiinfectives to treat infections caused by drug resistant bacterial and fungal pathogens. Daptomycin, the Company's lead product, is a unique agent with potent bactericidal activity that addresses the critical need for new antibiotics with potent activity against resistant infections. The Company plans to begin Phase III clinical trials of intravenous daptomycin in early 1999. Cubist is also applying its expertise in microbiology, genomics and medicinal chemistry to identify other novel compounds with a broad spectrum of activity against life-threatening infectious organisms such as methicillin resistant Staphyloccocus aureus (MRSA) and vancomycin resistant enterococci (VRE).

Devgen is a functional genomics and drug discovery company located in Flanders (Belgium). Devgen will enhance and accelerate the drug discovery process by using Caenorhabditis elegans - the tiny worm that is well known in the academic world as a standard tool for the study of animal developmental and cell biology.

The Dow Chemical Company is the fifth largest chemical company in the world, with annual sales of more than $20 billion. The company provides chemicals, plastics, energy, agricultural products, consumer goods and environmental services to consumers in virtually every country in the world.

Eli Lilly and Company is a global research-based pharmaceutical corporation headquartered in Indianapolis, Indiana, that is dedicated to creating and delivering pharmaceutical-based health care solutions which enable people to live longer, healthier and more active lives.

Eurand is a world leader in oral drug delivery. With manufacturing and research facilities in both the United States and Europe, Eurand is ideally positioned to service the global pharmaceutical market. Its technologies enable Eurand to provide extended release, delayed release, targeted delivery, oral peptide delivery and taste-masked dosage forms, resulting in optimization of drug absorption, reduction of side effects, improved palatability, reduction in dosing frequency and improved patient compliance.

FMC Corporation is one of the world's leading producers of chemicals and machinery for industry, government and agriculture. The company divides its businesses into four major segments: Performance Chemicals, Industrial Chemicals, Machinery and Equipment, and Defense Systems.

Genaissance Pharmaceuticals, Inc. develops and markets proprietary population genomics and informatics technologies designed to improve the productivity of the approximately $50 billion spent annually in drug discovery, development and marketing. The Company's technology has the potential to become a major catalyst in validating drug targets, improving the success rate of clinical trials and more profitably managing the life cycle of approved drugs. It is estimated that these efficiencies could save up to $200 million and two to three years in development time per drug.

Genelabs, a global biopharmaceutical and diagnostics company, is focused on gene-regulating drug discovery with an entirely new approach to medicine that could have profound potential in the treatment of many serious diseases. The company also has a late-stage product in clinical trials for systemic lupus erythematosus, an autoimmune disorder.

Genentech, Inc. is a biotechnology company using human genetic information to develop, manufacture and market pharmaceuticals that address significant unmet medical needs. Genentech commits itself to high standards of integrity in contributing to the best interests of patients, the medical profession, and its employees, and to seeking significant returns to its stockholders based on the continued pursuit of excellent science.

Genetics Institute, Inc. (GI), Cambridge, Massachusetts, U.S.A., is a leading biopharmaceutical company engaged in discovering, developing and commercializing therapeutic products to treat serious medical conditions and to improve quality of life. Organized in December 1980, GI currently focuses on compounds for the treatment of a wide range of diseases and conditions, including anemia, hemophilia, cancer, bone damage, inflammatory conditions and immune system disorders. Genetics Institute became a wholly owned subsidiary of American Home Products Corporation in December 1996.

Genome Systems has the largest number of commercially used picking and gridding robots in the world. Using our robotics and automation expertise, we tailor each project to your research needs and provide fast, accurate results.

Genomica Corporation is a leading pharmacogenomics software company. The company's tools combine clinical, epidemiology, genetic, molecular biology, and biochemistry applications into a single software environment that enables scientists to accelerate genetic discoveries and pharmacogenomics. Genomica's software is used in the gene discovery process to develop custom drug applications and accelerate time to market for new drugs. The software supports a range of research activities and provides data that can be accessed and used by pharmaceutical and biotechnology companies.

A highly diversified company, Genzyme uses a wide range of technologies to provide human health care products and services. The company has extensive capabilities in sales and marketing, manufacturing, research and development, and other disciplines necessary for success in the health care market.

Milton S. Hershey believed in making the highest quality product at an affordable price, ensuring consumers the best value for their money. This philosophy continues to guide Hershey Chocolate North America, the largest division of Hershey Foods and its operating units.

hte GmbH - the high throughput experimentation company - is an independent, privately-held high-science, high-technology company. The company was launched specifically to develop, validate and apply high throughput methods for the discovery and optimization of materials. hte GmbH focuses on catalytic and separative processes. These processes are critical to the global chemical industry, yet there are major unmet materials needs. hte GmbH was founded in March 1999 and commenced operations in June 1999.

Through its novel research and development programs, ImClone is developing a pipeline for potential products for cancer. Its innovative approaches have led to three distinct development programs: cancer therapeutics, cancer vaccines and anti-angiogenesis agents. Each of these programs has resulted in product candidates, some of which are advancing through clinical studies.

Based in Seattle, Washington, U.S.A., Immunex Corporation is a leading biopharmaceutical company founded in 1981 that discovers, develops, manufactures and markets products to treat cancer, autoimmune disorders and infectious diseases. American Home Products Corporation holds a majority interest in Immunex.

Immunomedics, Inc., founded in 1982, is a biopharmaceutical company focused on the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and infectious diseases. Integral to these products are highly specific monoclonal antibodies and fragments designed to deliver radioisotopes, chemotherapeutic agents, or toxins to tumors and sites of infection.

At Incyte Pharmaceuticals, we are combining our bioinformatics expertise with high-throughput DNA sequencing to create information- based tools for drug discovery and development. Our genomic databases, software, and biological reagents are rapidly becoming indispensable research components for pharmaceutical and biotechnology companies because they provide faster, easier, and more powerful ways for scientists to perform experiments, evaluate data, and create drugs.

Johnson & Johnson, with approximately 88,300 employees, is the world’s largest and most comprehensive manufacturer of health care products serving the consumer, pharmaceutical, diagnostics and professional markets. Johnson & Johnson has 164 operating companies in 50 countries around the world, selling products in more than 175 countries.

Karo Bio is a drug discovery company focusing its research on the discovery and pre-clinical phases of drug development. Research is conducted in the area of nuclear receptors. Nuclear receptors are proteins in the cell nucleus and act as receivers for a number of key hormones enabling the essential regulation of organs in the body. Through the understanding of nuclear receptors in drug design, new tissue selective drugs with fewer or no side effects can be developed.

Lexicon Genetics is a drug discovery company of the post-genome era, using gene knockout technology to define the functions of genes for the discovery of pharmaceutical products. We are expanding LexVision, our repository of new information on gene function, to fuel our drug discovery programs in cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and obesity. To generate our discoveries, we use our patented gene targeting and gene trapping technologies to alter the DNA of specific genes in mouse embryonic stem (ES) cells. These unique cells are cloned to create in vivo mammalian models of drug target function enabling the discovery of pharmaceutically valuable proteins and drug targets.

Ligand Pharmaceuticals is a San Diego based biopharmaceutical company committed to the discovery, development, marketing and distribution of novel, small molecule pharmaceutical products with novel patterns of receptor-specific selectivity which provide better efficacy or side effect profiles and more cost-effective alternatives to existing therapies.

Welcome to the T.J. Lipton Home Page, brought to you by the Lipton Internet team! Our mission is to provide net-surfers a place to explore information about Lipton, and to participate as a committed member of the Internet community.

MediChem Research, Inc. is a global contract research and development company assisting customers in accelerating the drug discovery process through innovation and technology in organic synthesis. MediChem is dedicated to becoming a valued collaborative partner in chemistry research through excellent scientific expertise, communication, and an outstanding track record since 1987.

Merck & Co., Inc. is a leading research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health. The Merck-Medco Managed Care Division manages pharmacy benefits for more than 40 million Americans, encouraging the appropriate use of medicines and providing disease management programs.

The prevention and treatment of disease... That is the mission, the heritage and the business of Merck Frosst Canada. Since the day Charles E. Frosst founded the Company in Montréal at the turn-of-the-century, Merck Frosst has been a leader in pharmaceutical research -- developing and producing medicines that respond to the health care needs of Canadians and people around the world.

Merial is the world's leading animal healthcare company dedicated to the research, development, manufacture and delivery of innovative pharmaceuticals and vaccines for use by veterinarians, farmers and pet owners to improve the health, well-being and performance of all animal species. The company is also market leader in the development and production of poultry breeding stock.

Founded in early 1993, Millennium Pharmaceuticals' principal objectives are to accelerate the discovery of disease-related genes and to produce validated targets and drug leads to enable the development of new, proprietary therapeutic and predictive medicine applications. The Company's research programs are focused on major common diseases which are under-served by current therapeutic alternatives, including obesity, type II diabetes, cardiovascular diseases, oncology, central nervous system disorders, respiratory disease, bacterial disease and fungal disease. Millennium has entered into significant, multi-year research and development partnerships with five major pharmaceutical partners. These alliances cover seven disease areas and provide over $300 million in committed funding. Located in Cambridge, Massachusetts, Millennium currently employs over 400 people.

Monsanto is made up of business sectors. Three of the sectors – Agricultural, Nutrition & Consumer Products and Pharmaceutical – are built around currently strong ongoing operations. Two others – Health & Wellness and Sustainable Development – pursue emerging opportunities.

Nabisco is a $7.7 billion multinational food business, manufacturing more than 200 brands and 8,000 products in 85 countries.

Nanosyn, Home of Nanoscale Combinatorial Synthesis Inc. We produce organic combinatorial libraries with unique design features as well as provide access to an existing compound collection approaching 100,000 individually purified and analytically characterized small molecules. All libraries are provided in 96 and 384 well plates, ready for redistribution or immediate screening.

Neurocrine has assembled a chemical library of diverse, low molecular weight organic molecules for lead compound identification. The Company has implemented robotic screening capabilities linked to its library of compounds that facilitate the rapid identification of new drug candidates for multiple drug targets. The Company believes that the utilization of high-throughput screening and medicinal and peptide chemistry will enable the rapid identification and optimization of lead molecules.

Neurogen is an emerging pharmaceutical company leading the design and development of a new generation of small molecule neuropharmaceuticals. Neurogen develops drugs to treat large markets with currently unmet needs through designing drug candidates (pills) with improved efficacy and fewer side effects than current therapies. Neurogen's ten drug development programs include drugs to treat anxiety, obesity, schizophrenia, sleep disorders, dementia, depression, stress-related disorders and epilepsy.

As a leading force in healthcare for over a century, Novartis is committed to improving the global quality of life through our broad portfolio of products and services in pharmaceuticals, generics, consumer health, and eye care and opthalmics. Novartis was formed by the merger of Ciba and Sandoz.

Oncogene Science, Inc. is a biopharmaceutical company involved in the discovery and development of novel drugs to treat or cure major human diseases. Independently, and in collaboration with four pharmaceutical partners, including Pfizer, Ciba-Geigy, Hoechst Marion Roussel, and the Wyeth-Ayerst Research division of American Home Products, Oncogene Science is currently pursuing 30 disease targets in areas such as cancer, cardiovascular disease, infectious diseases, and other diseases involving gene regulation. The Company is also developing cancer diagnostic products.

Ontogeny, Inc., founded in August 1994, is a privately-held biotechnology company whose mission is to be the pre-eminent biopharmaceutical company utilizing developmental biology to create therapeutics that will significantly improve the quality of life by activating the body's ability to repair and regenerate. Developmental biology is the study of how cells, tissues and organs change as they interact during development. Ontogeny's research is based on the process whereby an organism changes its size, shape and organization from a fertilized egg to a mature individual. The same processes and molecules that are active during development are reactivated in adult regenerative processes. Ontogeny is identifying ways to rejuvenate damaged systems by looking at the signaling processes of cells during development and restoring them in adults to trigger repair and regeneration.

Orchid BioSciences, Inc. is a leading provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT, its proprietary SNP analysis technology, and markets SNPstreamTM instruments and SNPwareTM consumables that rapidly generate highly accurate, cost effective SNP information. SNP-IT is usable in environments ranging from small-scale laboratories to large commercial facilities. Its versatility also has enabled Orchid to partner with industry leaders to make SNP-IT-enabled products available on a wide variety of instrument platforms. Orchid also provides high throughput SNP scoring services to pharmaceutical, biotechnology and academic customers through its MegaSNPatron facility, and DNA testing through its GeneScreen facilities that conduct paternity, forensics and transplantation testing. Through its Pharmaceutical Value Creation business, Orchid also seeks to identify proprietary medical applications of SNPs. More information on Orchid can be found at its web site www.orchid.com.

Organon is a pharmaceutical business unit of Akzo Nobel. It is registered in Oss, the Netherlands. The company has developed and manufactured ‘prescription-only’ drugs, principally hormone preparations, since 1923. The company’s most successful products are oral contraceptives (Marvelon and Mercilon), fertility hormones (Puregon and Pregnyl) and hormone replacement products for menopausal and post-menopausal women (Livial). But it has other important products which are used in psychiatry (Remeron, Risperdal and Tolvon) and in the prevention of thrombosis (Orgaran).

MDS Panlabs, Inc. is a contract research organization providing scientific research services supporting drug discovery, development, and process improvement to the pharmaceutical industry. Specific services include: natural products and new drug discovery; strain and yield improvement using molecular or classical approaches; and compound profiling, synthesis, isolation, and analysis.

Palatin Technologies, Inc. is a development stage biopharmaceutical company that is developing and testing products for diagnostic imaging, and peptide-based analogues that may have a wide range of pharmaceutical applications. PLTN's first two products are LeuTech(tm), a radiolabeled monoclonal antibody for infection imaging that has completed a company-sponsored Phase I trial, with the Company-sponsored Phase II trial for the diagnosis of equivocal appendicitis currently underway; PT-11, a peptide based infection imaging agent designed to address the Japanese diagnostic imaging market with development support from license and milestone payments from Nihon Medi-Physics of Japan; PT-14, a peptide-based sexual dysfunction therapeutic; and PT-5, a radiolabeled peptide-based cancer therapeutic that is in early stage development.

PharmaSeq, Inc. is a privately held start-up biotechnology company founded in 1996 with research and development facilities located in Monmouth Junction, NJ, near Princeton. The company has six patents from the U.S. Patent and Trademark Office covering microtransponder-based assays. PharmaSeq's strategy is to apply microtransponder technology initially to DNA diagnostic assays, a U.S. market estimated to reach over $1 billion by the year 2002 and then move forward in genomics, forensics, communications, pharmaceutical drug discovery, RFID and other areas.

PHASE-1 is a molecular and high throughput toxicology contract laboratory. We specialize in development and application of advanced assays for prioritization of lead compounds and understanding mechanisms of toxicity. For example, PHASE-1 is the only contract testing organization that can synthesize and analyze its own high density gene arrays in-house. Our arrays are designed specifically for toxicology. In addition, PHASE-1 is a pioneer in the field of bioinformatics applied to molecular toxicology. The primary goal of the scientists at PHASE-1 is to advance the field of molecular toxicology and to share these advances with the drug discovery and toxicology communities.

The ultimate objective of Pharmacia & Upjohn's research is to develop new, innovative medicines that can help people around the world live longer and fuller lives.

Located in Princeton, New Jersey, Pharmacopeia is a leader in drug discovery combining small molecule combinatorial chemistry, high-throughput screening, and informatics. Through its wholly-owned subsidiary, Molecular Simulations Inc., Pharmacopeia provides software sales and services to the life and materials science industries.

Two of the leading global contract research organizations have joined forces to become the third largest CRO in the world. With this merger, PPD Pharmaco has created the standard-setting partner for clinical development. On the one hand, we bring you far-reaching experience and therapeutic expertise. On the other, innovative technology and project management systems. The result is an unmatched resource for speeding pharmaceuticals, medical devices and biotechnology products to market.

PTC Therapeutics, Inc. has developed several novel, proprietary, and complementary platform technologies that rapidly identify small molecules affecting the availability, or utilization, of specific RNAs. The technologies are applicable to a diverse set of targets. These platforms identify lead compounds that alter the post-transcriptional control of the expression of specific genes and/or RNA function. In addition to their broad applicability to diverse therapeutic targets, these technologies are fast, cost-efficient, and performed under physiological conditions thereby enabling parallel screens to be undertaken simultaneously for a large number of drug discovery programs. PTC's platform technologies include: TRAC (Targeted Ribonucleic Acid Chemistry) - for the rapid screening and identification of small molecules that bind directly to RNA with high specificity and modulate RNA utilization. TRAC is performed under physiological conditions that allow targeted RNAs to retain their native structures. RNA-Screen Translation - for the screening and identification of small molecules that modulate different aspects of translation initiation, elongation and termination events in order to regulate the expression of genes relevant to both genetic and infectious diseases. RNA-Screen Turnover - for the screening and identification of small molecules that affect specific steps in cellular mRNA turnover and processing pathways. Molecules identified by this procedure can promote either substantial increases or decreases in mRNA levels.

Rib-X Pharmaceuticals, Inc. is a New Haven, CT-based small molecule drug discovery company focused on the structure-based design of classes of anti-infective agents. Our technology platform is based on the high resolution crystal structure of the 50S subunit of the ribosome obtained by Thomas Steitz, Peter Moore and their co-workers. Since the publication of their work (Science 289:905-929), their crystallography studies have advanced to include analysis of the structure of known antibiotics bound to the ribosome. The structural data from the antibiotic binding studies will be used at Rib-X to prime parallel lead optimization programs focused on evaluating new chemistry ideas about antibiotic interactions with the multiple binding domains or drug targets within the 50S subunit. Using proprietary computational chemistry tools provided by another scientific founder, Yale Professor William Jorgensen, coupled with chemical synthesis, biochemistry and crystallographic analysis, we aim to discover new compounds useful as anti-infective agents.

The Roche Group is one of the world's leading research-based healthcare groups active in the discovery, development, manufacture and marketing of pharmaceuticals and diagnostic systems. The Group is also one of the world's largest producers of vitamins and carotenoids and of fragrances and flavors.

Rohm and Haas is a manufacturer of specialty chemicals and plastics. Its products are those "invisible" ingredients that make things work better and last longer. The company's expertise in polymer design and small-molecule chemistry, along with a tradition of dynamic customer service, have made it one of the world's premier suppliers of specialty chemicals.

Sankyo Co.,Ltd

Schering-Plough is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health care products worldwide. The Company's central strategic objective is the discovery and development of novel therapeutics that can improve people's health and extend lives.

Small Molecule Therapeutics, Inc. (SMT) is a privately held drug discovery company. SMT uses proprietary whole-cell high throughput screening systems to discover novel compounds of therapeutic value for a broad range of disorders including cancer and immunological, infectious and metabolic diseases and for applications in agriculture.

In 1861, Ernest Solvay, a man with a passionate interest in science, research and innovation, developed a revolutionary ammonia-soda process for producing sodium carbonate. The Solvay Group was founded in 1863 to exploit this process, and has grown to become a global group of chemical and pharmaceutical companies specializing in four sectors: Chemicals, Plastics, Processing and Pharmaceuticals.

SOUTHERN RESEARCH INSTITUTE (SRI) is an independent, 501-(c)-3, not-for-profit center for scientific research with a staff of nearly 600, including scientists, technical, and staff support personnel. In late 1999 the Institute affiliated with the University of Alabama at Birmingham. Both institutions are recognized leaders in many fields of scientific inquiry and have collaborated successfully in the past and this new relationship will foster even greater, more fruitful cooperation in the future. The Institute works under contract for both public and private sector clients. SRI’s High Throughput Screening (HTS) program is a division of the Cancer Therapeutics and Immunology Department. The HTS program has integrated a large number of biochemical and cell-based screening assays from all Drug Discovery and Development Divisions within SRI, including cancer therapeutics, immunology, toxicology, and infectious disease. We specialize in determining the most cost-effective method for evaluating compound libraries without compromising assay sensitivity. Additionally, we welcome collaborations with companies in possession of compound libraries that have an interest in evaluating potential antiviral, anti-microbial or anti-cancer activity in addition to toxicological profiles of their compounds on a fee for service or compound licensing basis.

Symyx Technologies is pioneering the emerging field of combinatorial materials science by applying proprietary combinatorial methodologies to discover and develop new materials for the electronics and chemical industries. Through its technologies, the company is able to synthesize and screen materials, formulations, and microdevices up to 100,000 times faster than conventional "small batch" procedures. Symyx expects its ability to evaluate millions of inorganic, organic and organometallic compounds will lead to the rapid, cost effective discovery of materials for high-value products and applications.

Synthelabo   is a major French research-based pharmaceutical firm. Its Research Division, with a staff of 1350 specialised researchers, develops highly innovative drugs, mainly in the areas of central nervous system, cardiovascular and internal medicine.

The newest name in human cell transformation has a long and respected history. Since 1986 you've relied upon the International Institute for the Advancement of Medicine (IIAM) for your research needs. Now, in order to extend and enhance service to you, IIAM has formed Tissue Transformation Technologies (T-Cubed) to advance the processing technologies of the perfused organ program. T-Cubed is the solution for human tissue and organs that have been otherwise rendered unsuitable for transplantation. T-Cubed's advancing technology and growing expertise converts human organs and tissues into optimum in vitro models for research, drug metabolism / toxicity studies and compound screening (HTS).

Tripos, Inc. is a leading discovery research organization providing discovery informatics software, systems integration, chemical libraries and services for new compound research in life science applications worldwide.

Vertex Pharmaceuticals is a drug discovery and development company that has pioneered the application of structure-based drug design, a powerful drug discovery strategy to design orally deliverable, small molecule drugs. The Company is using this technology to design novel therapeutics for the treatment of HIV infection and AIDS, multidrug resistance in cancer, hemoglobin disorders, autoimmune disease, inflammation and hepatitis C.

Warner-Lambert is a premiere global marketer of vital prescription drugs and renowned consumer products that enrich the personal health and enjoyment of people around the world.

Whitehall-Robins Healthcare is a leader in the research and development, manufacturing and marketing of a broad range of consumer health care products. With 1996 U.S. sales of $1.4 billion, Whitehall-Robins is one of the largest over-the-counter (OTC) health care companies in the United States. Headquartered in Madison, New Jersey, U.S.A., it employs 1,700 people in the United States. Of the thousands of products in the U.S. non-prescription market today, three of the five top sellers are Whitehall-Robins products: Advil®, Robitussin® and Centrum®. Three recently introduced Whitehall-Robins OTC products include Orudis® KT, an adult analgesic, launched in November 1995; Axid® AR, an acid reducer, launched in July 1996; and Children's Advil®, a pediatric analgesic, launched in September 1996.

This is a World-Wide Web server run by the Center for Genome Research at the Whitehead Institute for Biomedical Research in Cambridge, Massachusetts, USA. It contains information on map and sequence releases, software and people at the Genome Center.

Wyeth-Ayerst is a major research-oriented enterprise serving the health needs of people in 145 countries. Wyeth-Ayerst has a long history of pioneering developments in pharmaceuticals and is a leader in the areas of women's health care, cardiovascular and metabolic disease therapies, anti-inflammatory agents, central nervous system drugs, oncology/immunology, infectious diseases, anti-infectives, vaccines and generic pharmaceuticals. Wyeth-Ayerst's principal products include Premarin® (conjugated estrogens tablets, USP), Prempro™ and Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets), Effexor® (venlafaxine hydrochloride tablets), Lodine® (etodolac capsules and tablets), Naprelan® (naproxen sodium controlled-release tablets), Ziac® (bisoprolol fumarate/hydrochlorothiazide tablets), Verelan® (verapamil HCl pellet-filled capsules) and Zosyn® (sterile piperacillin sodium/tazobactam sodium). The organization includes Wyeth-Ayerst Laboratories, Wyeth-Ayerst International, Inc. and Wyeth-Ayerst Research.

X-Ceptor Therapeutics is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from our in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents. X-Ceptor is developing a powerful technology platform that includes our in-house, state-of-the-art screening, combinatorial chemistry and molecular disease association using functional genomics. The development of these technologies offers the ability to streamline the discovery of new therapeutics and provides an untapped opportunity to expand drug discovery on these biologically and therapeutically important molecular targets.

XENOTECH offers one of the most extensive selections of products for drug metabolism-related research, including liver and pulmonary microsomes and S9, cryopreserved hepatocytes from human and six other toxicologically relevant species, antibodies directed against CYP enzymes, recombinant CYP's, and bDNA probe sets.

Zeneca is a leading international bioscience group active in three main areas of business - Pharmaceuticals, Agrochemicals and Specialties - which provide products and services to improve human health, nutrition and quality of life around the world.

ZymoGenetics is a targeted bioinformatics-driven company dedicated to the discovery and development of novel therapeutic agents used in the treatment and prevention of human illness.

Bioportfolio Limited intends to establish an interactive, one-stop location on global biotechnology activities. To date we have identified over 300 companies starting with "A" to "E", of which 170 are linked to their respective web site and 110 to NASDAQ. Over the next three months we anticipate that over 2500 companies will be listed on Bio-Corporate and that several companies and organisations will be actively participating in our BioLogo scheme, Bio-Wire, Bio-Vacancy and Bio-Mart services.

RUU Pharmaceutical Companies Links,  InfoLink, and .

PhRMA membership represents approximately 100 U.S. companies that have a primary commitment to pharmaceutical research. These companies are discovering, developing and bringing to market medicines that improve our health and quality of life--as well as reduce the overall cost of healthcare.